Abelacimab shows a 62% reduction in major or clinically relevant non-major bleeding compared to rivaroxaban in AFib patients. The study highlights an 89% reduction in gastrointestinal bleeding, a ...

Abelacimab showed a 60-70% reduction in bleeding events compared to rivaroxaban, leading to early trial termination. The trial's results suggest abelacimab could shift the standard of care by ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, ...

Testing two once-monthly doses of abelacimab against rivaroxaban (Xarelto), researchers found that abelacimab significantly reduced major or clinically relevant nonmajor bleeding at both the 90-mg ...

The incidence rate of major or clinically relevant nonmajor bleeding was 3.2, 2.6, and 8.4 events per 100 person-years with 150mg abelacimab, 90mg abelacimab, and rivaroxaban, respectively (hazard ...

The 90 mg dose of abelacimab reduced the same types of bleeding by 69%. In addition, the team found that both doses of abelacimab almost eliminated gastrointestinal bleeding compared to ...

Abelacimab is associated with reduced bleeding compared with rivaroxaban in patients with atrial fibrillation (AF) in different bleeding risk categories, with greater absolute decreases occurring ...

Abelacimab has a half-life of about 28 days, meaning that residual drug activity is expected to last beyond the monthly dosing interval. Due to the lack of relevant RCT data, periprocedural management ...

Abelacimab was well- tolerated overall, and injection-site reactions were uncommon. To TCTMD, Ruff said he is confident that the data support the 150-mg dose of abelacimab, which is what will be ...

Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy taking abelacimab as compared to rivaroxaban AZALEA-TIMI ...